Abbott says shipped millions of cans of infant formula from Ireland
Reuters
Published May 13, 2022 12:39PM ET
Updated May 13, 2022 02:21PM ET
(Reuters) -Abbott Laboratories said on Friday it has air shipped millions of cans of infant formula powder into the United States from its facility in Ireland to address shortages here as it tries to reopen its Michigan manufacturing plant.
The company said in a blog https://www.abbott.com/corpnewsroom/nutrition-health-and-wellness/abbott-update-on-powder-formula-recall.html it was shipping infant formula produced at its Cootehill, Ireland facility to be used by consumers eligible for the U.S. government's Women, Infants and Children (WIC) nutrition assistance program for low-income families.
Abbott in February recalled some baby formulas, including certain Similac products, made at the Sturgis plant after complaints about bacterial infections in infants who had consumed the products. It is working with the U.S. Food and Drug Administration to reopen the plant.
The company said it has also been working with the U.S. Department of Agriculture (USDA) and WIC agencies. In states where Abbott has the WIC contract, it will pay rebates on competing products if Similac is not available through August.
In a May 13 letter to Abbott Chairman Robert Ford, USDA Secretary Thomas Vilsack asked for the policy to be put in place through August instead of month-by-month.
The company also said it has prioritized infant formula production at its facility at Columbus, Ohio, converting other liquid manufacturing lines into making Similac liquid ready-to-feed.
Lack of supply from Abbott has exacerbated a broad shortage of baby formula, which was been hit by supply chain snags and historic inflation rates.
U.S. President Joe Biden met on Thursday with executives from infant formula manufacturers and retailers, pressing them to do everything possible to get families access.
Separately, the U.S. Centers for Disease Control and Prevention (CDC) closed its investigation on Abbott's infant formula, with no additional cases of infections, according to a notice on the FDA website.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.